Atovaquone是一种口服有效的选择性寄生虫线粒体细胞色素bc1复合物抑制剂。它对恶性疟原虫bc1的抑制活性显著高于对人类同源物,是一种具有研究疟疾、肺孢子虫肺炎、弓形体病及巴贝斯虫病潜力的抗疟剂。
|
英文别名 (English Synonym) |
Atovaquone |
|
中文名称 (Chinese Name) |
阿托伐醌 |
|
靶点 (Target) |
Anti-infection |
|
通路 (Pathway) |
Microbiology/Virology |
|
CAS号 (CAS NO.) |
95233-18-4 |
|
分子式 (Formula) |
C22H19ClO3 |
|
分子量 (Molecular Weight) |
366.84 |
|
纯度 (Purity) |
≥98% |
|
溶解性 (Solubility) |
溶于DMSO |
-25~-15℃保存，有效期3年
[1] Nilsen A, LaCrue AN, White KL, Forquer IP, Cross RM, Marfurt J, Mather MW, Delves MJ, Shackleford DM, Saenz FE, Morrisey JM, Steuten J, Mutka T, Li Y, Wirjanata G, Ryan E, Duffy S, Kelly JX, Sebayang BF, Zeeman AM, Noviyanti R, Sinden RE, Kocken CHM, Price RN, Avery VM, Angulo-Barturen I, Jiménez-Díaz MB, Ferrer S, Herreros E, Sanz LM, Gamo FJ, Bathurst I, Burrows JN, Siegl P, Guy RK, Winter RW, Vaidya AB, Charman SA, Kyle DE, Manetsch R, Riscoe MK. Quinolone-3-diarylethers: a new class of antimalarial drug. Sci Transl Med. 2013 Mar 20,5(177):177ra37. doi: 10.1126/scitranslmed.3005029. PMID: 23515079, PMCID: PMC4227885.[2]Schöler N, Krause K, Kayser O, Müller RH, Borner K, Hahn H, Liesenfeld O. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. Antimicrob Agents Chemother. 2001 Jun,45(6):1771-9. doi: 10.1128/AAC.45.6.1771-1779.2001. PMID: 11353624, PMCID: PMC90544.
